Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Common Equity: 2018-2024

Historic Common Equity for Neurogene (NGNE) over the last 4 years, with Dec 2024 value amounting to $310.4 million.

  • Neurogene's Common Equity rose 93.24% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year increase of 93.24%. This contributed to the annual value of $310.4 million for FY2024, which is 66.85% up from last year.
  • Per Neurogene's latest filing, its Common Equity stood at $310.4 million for FY2024, which was up 66.85% from $186.0 million recorded in FY2023.
  • In the past 5 years, Neurogene's Common Equity ranged from a high of $310.4 million in FY2024 and a low of $186.0 million during FY2023.
  • For the 2-year period, Neurogene's Common Equity averaged around $248.2 million, with its median value being $248.2 million (2023).
  • Data for Neurogene's Common Equity shows a peak YoY spiked of 66.85% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Neurogene's Common Equity stood at $186.0 million in 2023, then spiked by 66.85% to $310.4 million in 2024.